Mainz Biomed NV (NASDAQ:MYNZ) Sees Large Increase in Short Interest

Mainz Biomed NV (NASDAQ:MYNZ) was the target of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 322,531 shares, an increase of 26.3% from the January 15th total of 255,354 shares. Approximately 3.6% of the shares of the stock are sold short. Based on an average trading volume of 562,319 shares, the short-interest ratio is presently 0.6 days. Based on an average trading volume of 562,319 shares, the short-interest ratio is presently 0.6 days. Approximately 3.6% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Armistice Capital LLC boosted its holdings in Mainz Biomed by 38.4% in the third quarter. Armistice Capital LLC now owns 394,519 shares of the company’s stock valued at $588,000 after acquiring an additional 109,519 shares during the last quarter. Cerity Partners LLC purchased a new position in shares of Mainz Biomed in the 4th quarter worth about $183,000. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Mainz Biomed by 200.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after purchasing an additional 20,000 shares during the period.

Wall Street Analysts Forecast Growth

MYNZ has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday, December 22nd. Wall Street Zen raised shares of Mainz Biomed to a “hold” rating in a research note on Saturday, December 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Mainz Biomed Trading Up 6.5%

Shares of MYNZ stock traded up $0.05 during trading hours on Monday, hitting $0.80. 55,052 shares of the company were exchanged, compared to its average volume of 388,489. The firm has a fifty day moving average of $1.12 and a 200 day moving average of $1.36. The company has a quick ratio of 0.43, a current ratio of 0.52 and a debt-to-equity ratio of 0.44. Mainz Biomed has a 1 year low of $0.60 and a 1 year high of $6.66. The firm has a market cap of $7.25 million, a PE ratio of -0.01 and a beta of 0.26.

Mainz Biomed (NASDAQ:MYNZ) last released its earnings results on Friday, September 26th. The company reported ($1.32) earnings per share (EPS) for the quarter. The company had revenue of $0.14 million for the quarter. Analysts expect that Mainz Biomed will post -23.6 earnings per share for the current year.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.